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Abstract
Introduction: Increased levels of genes in the type I interferon (IFN) pathway have been observed in patients with
systemic sclerosis (SSc), or scleroderma. How type I IFN regulates the dermal fibroblast and its participation in the
development of dermal fibrosis is not known. We hypothesized that one mechanism by which type I IFN may
contribute to dermal fibrosis is through upregulation of specific Toll-like receptors (TLRs) on dermal fibroblasts.
Therefore, we investigated the regulation of TLR expression on dermal fibroblasts by IFN.
Methods: The expression of TLRs was assessed in cultured dermal fibroblasts from control and SSc patients
stimulated with IFNa2. The ability of IFNa2 to regulate TLR-induced interleukin (IL)-6 and CC chemokine ligand 2
production was also assessed. Immunohistochemical analyses were performed to determine whether TLR3 was
expressed in skin biopsies in the bleomycin-induced skin fibrosis model and in patients with SSc.
Results: IFNa2 increased TLR3 expression on human dermal fibroblasts, which resulted in enhanced TLR3-induced
IL-6 production. SSc fibroblasts have an augmented TLR3 response to IFNa2 relative to control fibroblasts.
Pretreatment of fibroblasts with transforming growth factor (TGF)-b increased TLR3 induction by IFNa2, but
coincubation of TGF-b did not alter TLR3 induction by IFN. Furthermore, IFNa2 inhibits but does not completely
block the induction of connective tissue growth factor and collagen expression by TGF-bin fibroblasts. TLR3
expression was observed in dermal fibroblasts and inflammatory cells from skin biopsies from patients with SSc as
well as in the bleomycin-induced skin fibrosis model.
Conclusions: Type I IFNs can increase the inflammatory potential of dermal fibroblasts through the upregulation of
TLR3.
Introduction
Systemic sclerosis (SSc), or scleroderma, is a multisystem
autoimmune disease clinically characterized by progressive
fibrosis of the skin and internal organs. Pathologically, SSc
exhibits three cardinal features: inflammation and autoim-
munity, vasculopathy and excessive extracellular matrix
(ECM) deposition [1]. The ECM consists of collagens, pro-
teoglycans, fibrillins and other matrix molecules [2].
Located within this matrix are fibroblasts and myofibro-
blasts, key effectors of the fibrotic process. Resident and
infiltrating cells in the dermis secrete soluble mediators,
such as transforming growth factor b (TGF-b), that acti-
vate fibroblasts and induce differentiation into myofibro-
blasts [3,4]. The myofibroblasts subsequently produce
large amounts of ECM, leading to fibrosis. In addition to
their role in ECM deposition, dermal fibroblasts and myo-
fibroblasts are capable of secreting inflammatory cytokines
and chemokines, such as interleukin (IL)-6 and CC che-
mokine ligand 2 (CCL-2), important inflammatory media-
tors in SSc pathogenesis [5-8]. Thus, fibroblasts also may
contribute to the development of dermal fibrosis through
the production of these inflammatory mediators.
Current paradigms point toward systemic immune
dysregulation as a central process that ultimately may
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any medium, provided the original work is properly cited.lead to fibroblast activation. Biopsies of early SSc skin
demonstrate perivascular infiltrates of mononuclear
inflammatory cells, which produce cytokines and che-
mokines that recruit inflammatory cells and promote
ECM deposition [9]. More recent studies in patients
with SSc have identified dysregulation of type I inter-
feron (IFN) pathways similar to those seen in patients
with systemic lupus erythematosus (SLE) [10-12]. Gene
expression profiling of peripheral blood has demon-
strated the presence of a type I IFN signature in patients
with SSc [12]. These findings have been confirmed in
both circulating CD14
+ monocytes and CD4
+ T-cells, as
well as in skin biopsies from patients with SSc compared
with healthy controls [13-15]. Together these data
demonstrate the presence of a type I IFN signature in
circulating blood cells and a major target organ (skin) in
patients with SSc.
Type I IFNs are potent regulators of the immune sys-
tem, where they modulate the differentiation, survival,
proliferation and cytokine production of T-cells, B-cells
and dendritic cells. Among the critical immunoregula-
tory functions of IFN is its ability to stimulate the
expression of Toll-like receptors (TLRs) on dendritic
cells. TLRs are a family of germ line-encoded proteins
that serve as pattern recognition receptors capable of
recognizing highly conserved motifs present in infec-
tious microorganisms called pathogen-associated mole-
cular patterns (PAMPs) [16]. While their roles are best
characterized on antigen-presenting cells, various TLRs
also are expressed on fibroblast populations [17,18].
Interestingly, IFN increases TLR3 and TLR7 expression
on fibroblast-like synoviocytes (FLS) and enhances TLR-
induced inflammatory cytokine production by FLS [18].
Given the reported influence of IFN on FLS and the
importance of dermal fibroblasts in the pathogenesis of
SSc, it is important to understand how IFN may modu-
late the dermal fibroblast. We hypothesized that one
mechanism by which type I IFN may contribute to the
pathogenesis of SSc is through upregulation of the
expression of specific TLRs on dermal fibroblasts.
Materials and methods
Reagents
Recombinant human TGF-b and IFNa2 were purchased
from eBioscience Inc. (San Diego, CA, USA). TLR ago-
nists Pam3CysK4; polyinosinic:polycytidylic acid, or poly
(I:C); lipopolysaccharide (LPS) and Gardiquimod ([1-(4-
amino-2-ethylaminomethylimidazo[4,5-c]quinolin-1-yl)-
2-methylpropan-2-ol]) were purchased from InvivoGen
(San Diego, CA, USA).
Fibroblast cultures
Skin biopsy specimens of clinically uninvolved skin were
obtained from patients with SSc and from control
patients without a history of autoimmune disease. All
patients with SSc fulfilled the American College of
Rheumatology criteria for SSc [19]. All patients provided
written consent, and the study was approved by the
Committee for the Protection of Human Subjects at the
University of Texas Health Science Center at Houston.
Dermal fibroblast cultures were isolated as previously
described [20]. Cultured fibroblast strains were estab-
lished by mincing tissues and placing them into 60-
mm culture dishes secured by glass coverslips. The pri-
mary cultures were maintained in Dulbecco’sm o d i f i e d
Eagle’s medium (DMEM), 10% fetal bovine serum
(FBS), 2 mM L-glutamine, 100 U/mL penicillin, and 50
μM 2-mercaptoethanol at 37°C with 5% CO2.P a s s a g e s
4-8 dermal fibroblasts were used for experiments.
RNA isolation and quantitative real-time polymerase
chain reaction
Fibroblasts (3 × 10
4)w e r ec u l t u r e di n1 0 0μLD M E M
with 10% FBS in 96-well plates overnight. Cultures were
subsequently rested overnight in DMEM with bovine
serum albumin (BSA), then stimulated with cytokines in
DMEM with BSA for 24 hours. Total RNA was isolated
and cDNA was synthesized using the TaqMan Gene
Expression Cells-to-CT™ Kit (Applied Biosystems Inc.,
Foster City, CA, USA). Quantitative real-time PCR (qRT-
PCR) was performed using validated TaqMan Gene
Expression assays for human TLR2 (Hs00152973_m1),
TLR3 (Hs01551078_m1), TLR4 (Hs01060206_m1), TLR7
(Hs00152971_m1), TLR9 (Hs00152973_m1), connective
tissue growth factor (CTGF) (Hs00170014_m1) and
cyclophilin (Hs99999904_m1) (Applied Biosystems Inc.)
on an Applied Biosystems 7900HT Fast Real-Time PCR
System. Cyclophilin was used as an endogenous control
to normalize transcription levels of total RNA in each
sample. The data were analyzed using SDS 2.3 software
(Applied Biosystems Inc., Foster City, CA, USA) and the
comparative CT method (2-
ΔΔC
T method). The fold




Fibroblasts (3 × 10
5) were cultured in 1 ml DMEM with
10% FBS in 24-well plates overnight. Cultures were sub-
sequently rested overnight in DMEM with BSA, then
stimulated with TLR agonists (10 μg/mL) in DMEM
with BSA for 48 hours. Supernatants were harvested
and frozen at -80°C. IL-6 and CCL-2 levels were deter-
mined by performing enzyme-linked immunosorbent
assay (eBioscience, Inc.).
Bleomycin dermal fibrosis mouse model
Six- to eight-week-old female C57BL/6 mice (Jackson
Laboratory, Bar Harbor, ME, USA) were used in these
studies. The protocols were approved by the University
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Care and Use Committee. Filter-sterilized bleomycin
0.02 U per mouse was dissolved in phosphate-buffered
saline (PBS) (Teva Parenteral Medicines, Irvine, CA,
USA), or PBS was administered by daily subcutaneous
injections for 28 days into the shaved backs of mice
using a 27-gauge needle. At the end of the experiment,
mice were humanely killed and lesional skin was pro-
cessed for analysis.
Immunohistochemistry
Skin biopsies were obtained from four patients with SSc
and from four healthy controls without a known history
of autoimmune disease from the National Disease
Research Interchange (Philadelphia, PA, USA). Five-
micrometer sections were deparaffinized, rehydrated and
immersed in Tris-buffered saline and 0.1% Tween
20, then treated with target retrieval solution (Dako,
Carpinteria, CA, USA) at 95°C for 10 minutes. Rabbit
polyclonal primary antibodies against TLR3 or an iso-
type-matched control antibody (Abcam Inc., Cambridge,
MA, USA) were used. Bound antibodies were detected
using secondary antibodies from the Dako Cytomation
Envision System-HRP (3,3-diaminobenzidine tetrahy-
drochloride). Sections were counterstained with
hematoxylin.
Statistical analysis
Data were imported into GraphPad Prism software for
graphing and analysis (GraphPad Software, Inc., La Jolla,
CA, USA). Data are given as means, and error bars
represent the standard error of the mean. Nonpara-
metric paired (Mann-Whitney U test) and unpaired
(Wilcoxon signed-rank test) t-tests were used when
appropriate.
Results
TLR3 upregulation by IFN-a2 in cultured dermal
fibroblasts
Dermal fibroblasts from controls were stimulated with
media or human recombinant IFNa2 for 24 hours.
Total RNA was isolated and qRT-PCR was performed
to determine the relative expression of TLR2, TLR3,
TLR4, TLR7, TLR8 and TLR9. As shown in Figure 1A,
TLR3 expression was upregulated by IFNa2( 5 0 -
150 ng/mL) at 6 hours and remained elevated at 24 and
48 hours. In contrast, TLR4 expression was slightly
upregulated by IFNa2a t6h o u r s ,b u ta t2 4a n d4 8
hours no change in TLR4 expression was observed com-
pared with dermal fibroblasts cultured in media alone.
Expression of TLR2, TLR7, TLR8 and TLR9 was below
the limits of detection (data not shown). Additional
e x p e r i m e n t sd e m o n s t r a t e dt h a tT L R 3b u tn o tT L R 4
expression was upregulated in a dose-dependent fashion
(Figure 1B), with a concentration as little as 1 ng/mL
IFNa2 stimulating the expression of TLR3. These data
clearly demonstrate the upregulation of TLR3 expres-
sion by IFNa2 in control dermal fibroblasts.
The upregulation of TLR3 expression by IFNa2w a s
compared between SSc and control dermal fibroblasts.
The magnitude of induction of TLR3 expression by
IFNa2 was significantly greater in dermal fibroblasts
from patients with SSc than in controls (Figure 2A).
This increase in TLR3 expression was observed when
dermal fibroblasts were stimulated with IFNa2a t
concentrations from 1 to 100 ng/mL, although at
100 ng/mL the difference was not statistically significant
(Figure 2B). These data demonstrate that SSc cultured
fibroblasts have a greater magnitude of upregulation of
TLR3 by IFNa2 than that of control fibroblasts.
IFNa2 increases TLR3-induced IL-6 production in cultured
dermal fibroblasts
To determine whether the upregulation of TLR3 mRNA
resulted in changes in functional TLR levels, dermal
fibroblasts were preincubated with media alone or with
50 ng/mL IFNa2 for 24 hours. Cultures were subse-
quently stimulated with a panel of TLR agonists, and
cytokine and chemokine production were assessed.
Pam3CysK4 (a TLR2 agonist), poly(I:C) (a TLR3 agonist),
LPS (a TLR4 agonist) and Gardiquimod (a TLR7/8 ago-
nist) were all used at 10 μg/mL (Figure 3A).
Culture supernatants from control dermal fibroblasts
stimulated with the TLR3 agonist poly(I:C) produced
high levels of IL-6 and CCL-2. Preincubation of dermal
fibroblasts with IFNa2 resulted in increased IL-6 pro-
duction (P = 0.01) but not CCL-2 production compared
with dermal fibroblasts preincubated with BSA. Consis-
tent with the qRT-PCR data shown in Figure 1, preincu-
bation with IFNa2 did not significantly increase
TLR4-induced production of IL-6 or CCL-2. Last, while
IFNa2 preincubation slightly increased the levels of IL-6
and CCL-2 in cultures stimulated with TLR2 or TLR7/8
agonists, these levels were not higher than those of
unstimulated dermal fibroblasts (data not shown). These
data suggest that IFNa2 preincubation results in
enhanced IL-6 production to the TLR3 agonist poly(I:C).
SSc dermal fibroblasts also demonstrated enhanced
IL-6 production to the TLR3 agonist poly(I:C), but not
to other TLR agonists. In Figure 3B, the level of IL-6 in
culture supernatants from cells preincubated with
IFNa2 followed by TLR3 stimulation with poly(I:C) was
significantly higher than that in SSc dermal fibroblasts
preincubated in media alone followed by poly(I:C) sti-
mulation (P = 0.002). In contrast, IFNa2p r e i n c u b a t i o n
did not significantly increase poly(I:C)-induced produc-
tion of CCL-2. The IL-6 production in TLR2-stimulated
cultures was not higher than that in media alone (data
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with IFNa (50-150 ng/mL) or 0.1% bovine serum albumin (BSA) for 6, 24 and 48 hours. Total RNA was harvested, and (A) TLR3 and (B) TLR4
mRNA levels were determined by performing quantitative real-time polymerase chain reaction (qRT-PCR) assays. IFN induced TLR3 upregulation
at 6, 24 and 48 hours. TLR4 upregulation was noted only at 6 hours. (C) Dose-response curve for TLR3 upregulation by IFNa (0-100 ng/mL) for
24 hours in healthy control dermal fibroblasts. n = 3 control cell lines.
Normal Scleroderma
Figure 2 Comparison of TLR3 upregulation by IFNa in healthy control and systemic sclerosis (SSc), or scleroderma, dermal fibroblasts.
(A) Dermal fibroblasts were stimulated for 24 hours with 50 ng/mL IFNa, and TLR3 was determined by performing qRT-PCR assays. The
magnitude of induction of TLR3 expression by IFNa was significantly greater in dermal fibroblasts from patients with SSc (n = 11) than in those
from healthy controls (n = 25; P = 0.003). (B) SSc dermal fibroblasts have a greater magnitude of upregulation of TLR3 with IFN at
concentrations ranging from 1 to 100 ng/mL (n = 4 in each group; *P < 0.05 (Wilcoxon signed-rank test)).
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cally upregulates TLR3 expression in dermal fibroblasts,
which results in increased IL-6 production upon TLR3
stimulation of dermal fibroblasts.
Myofibroblasts have increased upregulation of TLR3
SSc skin biopsies have increased numbers of myofibro-
blasts [3]. In vitro TGF-b induces the differentiation
from fibroblasts to myofibroblasts [21]. Since SSc fibro-
blasts have an increased induction of TLR3 by IFNa2
compared with control fibroblasts, we sought to deter-
mine whether IFNa2 induction of TLR3 expression was
increased in myofibroblasts.
Control dermal fibroblasts were cultured in TGF-b for
72 hours to induce myofibroblast differentiation in vitro,
followed by stimulation with IFNa2 for 24 hours. As
expected, TGF-b increased the number of cultured
fibroblasts expressing a-smooth muscle actin as
detected using immunofluoresence (data not shown).
Interestingly, dermal fibroblasts preincubated with TGF-
b had greater induction of TLR3 by IFNa2 compared
with fibroblasts preincubated in media alone (14.83 ±
2.06 vs. 7.46 ± 1.62; P = 0.02) (Figure 4A). In contrast,
dermal fibroblasts preincubated with TGF-b had a
decrease in TLR4 induction by IFNa2 compared with
fibroblasts preincubated in media alone (1.1 ± 0.1 vs. 1.6
±0 . 1 ;P = 0.001). Therefore, myofibroblasts display
increased upregulation of TLR3 in response to IFNa2.
Coincubation of IFNa2 and TGF-b
Multiple lines of evidence point to the dysregulation of
TGF-b and IFNa2 in SSc [12,22]. How these two cyto-
kines interact at the level of the dermal fibroblasts has
not been fully elucidated. TGF-b has profibrotic proper-
ties, while previous studies have suggested that IFN may
have antifibrotic properties. It is reasonable to
Figure 3 IFN increases TLR3-induced interleukin (IL)-6 production in cultured dermal fibroblasts. (A) Healthy control fibroblasts (n = 10)
and (B) SSc dermal fibroblasts (n = 10) were preincubated with media alone or with 50 ng/mL IFNa for 24 hours, washed and then stimulated
with Pam3CysK4 (TLR2 agonist); polyinosinic:polycytidylic acid, or poly(I:C) (TLR3 agonist); lipopolysaccharide (TLR4 agonist) and Gardiquimod
(TLR7/8 agonist; [1-(4-amino-2-ethylaminomethylimidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol]) for 48 hours (10 μg/mL). Culture supernatants
were assessed for IL-6 and CC chemokine ligand 2 (CCL2). Preincubation with IFNa increased poly(I:C)-stimulated IL-6 but not CCL2 production
from healthy control and SSc dermal fibroblasts. *P < 0.05, **P < 0.01 (Wilcoxon signed-rank test).
Agarwal et al. Arthritis Research & Therapy 2011, 13:R3
http://arthritis-research.com/content/13/1/R3
Page 5 of 10hypothesize that dermal fibroblasts might be exposed
simultaneously to both IFNa2a n dT G F - b in vivo.
Therefore, we next sought to ascertain the effects of the
IFNa2-induced TLR3 upregulation during simultaneous
exposure to TGF-b.
Fibroblasts were incubated with IFNa2, TGF-b or
both cytokines for 24 hours. Total RNA was harvested
for qRT-PCR analysis (Figure 4B). TLR3 expression was
increased by IFNa2 in both control and SSc fibroblasts.
Coincubation of fibroblasts with IFNa2a n dT G F - b did
not change the expression of TLR3 compared with
IFNa2 alone. CTGF and type I collagen expression also
were assessed to determine whether concentrations of
IFNa2 that induced TLR3 have antifibrotic properties.
CTGF expression was increased by TGF-b in both con-
trol and SSc fibroblasts (20.04 ± 4.6 and 30.13 ± 10.62,
respectively). IFNa2 resulted in a slight nonsignificant
decrease in TGF-b-stimulated CTGF expression in both
control and SSc fibroblasts (18.27 ± 3.9 and 19.17 ±
2.58, respectively). Furthermore, collagen, type I, a1
(COL1A1) expression was increased by TGF-b in both
healthy control and SSc fibroblasts (3.90 ± 0.60 and 4.34
± 0.58, respectively). IFNa2 resulted in a slight decrease
in COL1A1 expression in both control and SSc fibro-
blasts; however, this difference was significant only in
the SSc fibroblasts (3.25 ± 0.41 and 3.13 ± 0.58, respec-
tively). The expression of CTGF and COL1A1 was sig-
nificantly higher in dermal fibroblasts stimulated with
both IFNa2 and TGF-b compared with media or IFNa2
alone, suggesting that IFNa2 only blunted the TGF-b
induction of CTGF and COL1A1. These data suggest
that IFNa2 may decrease expression of matrix-related
genes important in the development of dermal fibrosis;
however, at concentrations that induce TLR3 expression,
Figure 4 Cross-regulation of IFNa and TGFb in dermal fibroblasts. (A) Healthy control dermal fibroblasts were cultured in 10 ng/mL TGFb
for 72 hours to induce myofibroblast differentiation in vitro. After 72 hours, cultures were washed and subsequently stimulated with 50 ng/mL
IFN for 24 hours. Total RNA was analyzed for TLR3 by qRT-PCR assay. Preincubation with TGFb resulted in a greater induction of TLR3 by IFN
compared with fibroblasts preincubated in 0.1% BSA (n = 7; P = 0.02). (B) Dermal fibroblasts were incubated with 50 ng/mL IFN, 10 ng/mL TGF-
b or both cytokines for 24 hours. Total RNA was analyzed for TLR3, connective tissue growth factor (CTGF), and collagen type I, a1 (COL1A1)
expression by qRT-PCR assay. Coincubation of fibroblasts with IFN and TGF-b did not alter the expression of TLR3 compared with IFN alone. IFN
did not alter TGF-b-induced CTGF expression but did slightly reduce COL1A1 expression in SSc dermal fibroblasts. n = 7, *P < 0.05, n.s. = not
significant (Wilcoxon signed-rank test).
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with the overall induction by TGF-b alone.
TLR3 expression in fibrotic and scleroderma skin
The data above were obtained using cultured dermal
fibroblasts. To determine whether TLR expression is
also found in the fibroblasts in vivo, immunohistochem-
ical studies were performed to localize the expression of
TLR3 in skin from the bleomycin-induced skin fibrosis
model (Figure 5A), as well as from the skin biopsies of
healthy controls and patients with SSc (Figure 5B).
Skin biopsies were performed on mice injected daily
for 28 days with subcutaneous saline or bleomycin.
Staining with an antibody specific for TLR3 did not
reveal any detectable level of TLR3 expression in saline-
injected skin (Figure 5A, histograms a and b). In con-
trast, skin biopsies from mice injected with bleomycin
demonstrated expression of TLR3 that was present in
cells of the dermis (Figure 5A, histogram d), which loca-
lized to fibroblast-like cells (Figure 5A, histogram e) as
well as some inflammatory cells (Figure 5A, histogram
f). These data demonstrate that TLR3 expression is
increased in the dermis of mice injected with bleomycin.
To determine whether TLR3 is expressed in human
skin, immunohistochemistry was performed for TLR3 in
healthy control skin biopsies and SSc skin biopsies.
TLR3 expression was not detectable in the dermis of
healthy control skin (Figure 5B, histograms g-i). In con-
trast, TLR3 expression was observed with higher-power
magnification in the dermis of SSc skin (Figure 5B, his-
togram k) which was localized to fibroblast-like cells as
well as inflammatory cells (Figure 5B, histogram l). Last,
in SSc skin, the endothelial cells also demonstrated
expression of TLR3 (Figure 5B, histogram m), which
was not observed in healthy control skin biopsies.
Therefore, similar to the in vitro data, TLR3 is expressed
on fibroblasts in SSc biopsies.
Discussion
In the current article, we have demonstrated that
IFNa2, a type I interferon, increases the expression of
TLR3 on human dermal fibroblasts, which results in
enhanced TLR3-induced IL-6 production. Dermal fibro-
blasts from patients wit hS S ch a v ea na u g m e n t e d
response to IFN with regard to TLR3 expression. Con-
sistent with the in vitro data, we also have demonstrated
that skin biopsies from patients with SSc as well as the
bleomycin-induced skin fibrosis model both have TLR3
expression that localizes to fibroblast-like cells. Impor-
tantly, pretreatment with TGF-b increased TLR3 induc-
tion by IFNa2, but coincubation of TGF-b does not
alter TLR3 induction by IFNa2. Last, IFNa2 inhibits but
does not completely block the induction of CTGF and
collagen expression by TGF-b in dermal fibroblasts.
TLR3 is a member of the TLR family that recognizes
double-stranded RNA, which is a molecular pattern pro-
duced by many viruses at some point in their infectious
cycle [17]. TLR3 is expressed on endosomes of dendritic
cells, but has been reported on the cell surface as well
as in endosomes of fibroblasts [17]. Activation of TLR3
results in the production of type I IFN, which may in
turn further upregulate the expression of TLR3. With
regard to dermal fibroblasts and SSc, the potential TLR3
ligands are unknown. While viral triggers can be consid-
ered, there are no consistent associations of SSc with
specific viral infections. It is intriguing to hypothesize
that complexes of self-RNA andantimicrobial peptides,
which have been reported to stimulate TLR7 and TLR8
[23], could also activate TLR3, but this is speculative.
One additional hypothesis is that the ECM itself may
serve as a TLR3 ligand. Indeed, in addition to PAMPs,
TLRs can be activated by damage-associated molecular
patterns (DAMPs). DAMPs are proinflammatory mole-
cules generated upon tissue injury that include those
released from necrotic cells as well as from the ECM.
Tenascin-C has recently been reported to activate TLR4
during the development of inflammatory arthritis [24].
In the current study, the expression of TLR3 in human
skin was demonstrated on dermal fibroblasts within
dense connective tissue of the dermis. It is intriguing to
hypothesize that the ECM may contain TLR3 ligands
that could activate the dermal fibroblasts, even in the
absence of a viral trigger.
The function of TLRs is best characterized in the
innate immune system, where TLRs signal the presence
of an infection and direct the adaptive immune response
against microbial antigens [16]. The role of TLR signal-
ing in fibroblasts is not as clearly understood. TLR sti-
mulation of different fibroblast populations has been
demonstrated to increase the production of chemokines
and cytokines by fibroblasts, which subsequently can
increase the inflammatory infiltration of the tissue. In
this study, IFNa2 upregulated TLR3 and TLR3-induced
IL-6 production. The increase in IL-6 could contribute
to dermal fibrosis through increased fibroblast survival
and proliferation, ECM deposition and myofibroblast
differentiation [25-27]. In addition, IL-6 may act syner-
gistically with TGF-b with regard to the development of
tissue fibrosis [28]. Last, TLR3 activation may also
directly regulate the behavior of fibroblasts. A recent
report has demonstrated that TLR3 activation with poly
(I:C) increased ECM and a-smooth muscle actin pro-
duction, a marker of myofibroblast differentiation, by
lung fibroblasts [29]. Together the effects of TLR3
directly on dermal fibroblast ability to differentiate into
a myofibroblast and through the production of IL-6 may
contribute to the development of dermal fibrosis.
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the type I IFN pathways are upregulated in patients with
SSc compared with healthy controls [10-15]. However,
t h er o l eo ft y p eII F N si nt h ep a t h o g e n e s i so fS S c
remains to be determined. Plasmacytoid dendritic cells
( p D C s )a r et h ep r i m a r ys o u r c eo ft y p eII F N si nS L E
[10,30]. It also has been suggested that pDCs are key
producers of type I IFNs in SSc [31,32]. Type I IFNs
subsequently regulate the behavior of key cells involved
in the development of SSc, including dendritic cells, T-
cells and dermal fibroblasts. This regulation of dermal
fibroblasts could potentially be a pathologic or a protec-
tive response. In contrast to Th2 cytokines IL-4 and IL-










































Figure 5 Immunohistochemical analyses of TLR3 expression in dermal fibrosis. Immunohistochemical analyses were performed using
rabbit polyclonal antibodies against TLR3 (histograms a, b, d-f, g-i, k-m) or isotype control (histograms c and j). (A) Skin biopsies from mice
injected with bleomycin, but not saline, demonstrated expression of TLR3 in the dermis (panel d), which localized to fibroblast-like cells
(histogram e) and inflammatory cells (histogram f). n = 3 saline, n = 3 bleomycin. (B) Skin biopsies from control skin (n = 4) and SSc skin (n = 4)
demonstrated TLR3 expression in the dermis of SSc skin (histogram k), which localized to fibroblast-like cells and inflammatory cells (histogram l)
as well as to endothelial cells (histogram m) in SSc but no control skin.
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[33-37]. Type I IFNs havea l s ob e e nr e p o r t e dt o
decrease collagen production by dermal fibroblasts in
vitro [35,36]. Consistent with the in vitro effects of
IFNa2 on collagen production, administration of IFN-g
to mice decreased dermal fibrosis and collagen deposi-
tion in the bleomycin-induced skin fibrosis model [38].
However, clinical trials of recombinant IFN-g or IFN-a
in patients with SSc failed to show substantial clinical
benefit [39-41]. The lack of effect of IFNs in SSc may be
due to the timing of administration, the particular pre-
parations of IFNs, pharmacokinetics or other clinical
reasons. Alternatively, type I IFNs may have additional
effects on the behavior of dermal fibroblasts that are
independent of their antifibrotic properties.
T h ed a t ap r e s e n t e dh e r e i ns u g g e s tt h a tt y p eII F N s
may increase the inflammatory potential of the dermal
fibroblast in part through the upregulation of TLR3
expression. Furthermore, IFNa2 increases the inflamma-
tory potential more in SSc fibroblasts than in normal
fibroblasts. We observed these effects at concentrations
as low as 1 ng/mL IFNa2. The levels of IFNa2w i t h i n
the microenvironment of the skin are not known.
Therefore, it remains possible that the levels of IFNa2
used in the current study are higher than those found in
vivo. At concentrations capable of inducing TLR3
expression, IFNa2o n l ym a r g i n a l l yb l u n t e dT G F - b-
induced collagen production, which itself was still signif-
icantly elevated relative to unstimulated dermal
fibroblasts. Interestingly, it has recently been reported
that TLR3 stimulation of dermal fibroblasts increased
the expression of IFNa2- and TGF-b-responsive genes
and that mice treated with subcutaneous TLR3 agonists
developed dermal inflammation followed by fibrosis
[42]. Together these observations suggest that IFNs may
contribute to the development of SSc in a stepwise
model wherein the pDCs produce type I IFNs, which
regulate not only inflammatory cells but also dermal
fibroblasts. Type I IFNs might then increase the expres-
sion of a number of molecules on the dermal fibroblast,
including TLR3. TLR3 activation, either through viruses
or through DAMPs, could increase the inflammatory
potential of the dermal fibroblast, including increased
IL-6 production, and could further increase IFN- and
TGF-b-responsive gene expression. Together it is possi-
ble that the net balance would ultimately lead to the
development of dermal inflammation and fibrosis. In
vivo mouse studies will be helpful in determining the
overall balance between the antifibrotic and proinflam-
matory properties of IFNs.
Conclusions
In summary, our observations suggest that type I IFNs
can increase the inflammatory potential of the dermal
fibroblast through upregulation of TLR3 and its down-
stream responses. These studies add to our understand-
ing of how type I IFNs, which are increased in SSc, may
contribute to the pathogenesis of SSc. Additional studies
are needed to further clarify how type I IFNs may contri-
bute to SSc pathogenesis and to help determine whether
type I IFNs can be a rational therapeutic target in SSc.
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